Protocol No.: COMB157GUS10

AGNOS: An 18-month, Open-label, Multi-Center Phase IV Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes
Principal Investigator
Ward, Melanie
Phase
III/IV
Age Group
Adult
Applicable Disease Site
Neurology
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Lauren Chase, RN
Clinical Research Specialist
Phone: +1 304-598-4000

View on ClinicalTrials.gov